We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · October 21, 2021

Omecamtiv Mecarbil for Severe Heart Failure

JAMA Cardiology


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Cardiology
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial
JAMA Cardiol 2021 Oct 13;[EPub Ahead of Print], GM Felker, SD Solomon, B Claggett, R Diaz, JJV McMurray, M Metra, I Anand, MG Crespo-Leiro, U Dahlström, E Goncalvesova, JG Howlett, P MacDonald, A Parkhomenko, J Tomcsányi, SA Abbasi, SB Heitner, T Hucko, S Kupfer, FI Malik, JR Teerlink

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading